Key statistics
As of last trade Veracyte Inc (12V:DUS) traded at 37.00, -1.07% below its 52-week high of 37.40, set on Nov 14, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 37.00 |
---|---|
High | 37.00 |
Low | 37.00 |
Bid | 37.00 |
Offer | 37.60 |
Previous close | 37.20 |
Average volume | 3.78 |
---|---|
Shares outstanding | 77.50m |
Free float | 76.89m |
P/E (TTM) | -- |
Market cap | 3.02bn USD |
EPS (TTM) | -0.1445 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 11:30 GMT.
More ▼
Press releases
- Veracyte Announces Third Quarter 2024 Financial Results
- Veracyte to Participate in Upcoming Investor Conferences
- Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024
- New Data Presented at ASTRO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Aggressive Prostate Cancer in African American Men
- New Data Presented at ESMO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
- Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors
- Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
- Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle
More ▼